2. Search Result
Search Result
Results for "

(S)-β-Aminoisobutyric acid

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

3

Peptides

2

Natural
Products

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-113380
    (S)-β-Aminoisobutyric acid
    1 Publications Verification

    		 Endogenous Metabolite Drug Isomer Apoptosis AMPK Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    (S)-β-Aminoisobutyric acid is an orally active S-isomer of β-Aminoisobutyric acid (HY-W012974). (S)-β-Aminoisobutyric acid can be produced through the catabolism of thymine and valine. (S)-β-Aminoisobutyric acid reduces apoptosis and increases the ratio of p-AMPK. (S)-β-Aminoisobutyric acid has cardioprotective effects. (S)-β-Aminoisobutyric acid is associated with acute aerobic exercise .
    (S)-β-Aminoisobutyric acid
  • HY-W023323
    (S)-β-Aminoisobutyric acid hydrochloride
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    (S)-β-Aminoisobutyric acid hydrochloride is a cytoprotective agent, which is a non-proteinogenic amino acid enantiomer derived from valine metabolism in skeletal muscle mitochondria. The plasma level of (S)-β-Aminoisobutyric acid hydrochloride increases significantly after acute aerobic exercise (and is not affected by the AGXT2 rs37369 genotype), and it is secreted by mouse extensor digitorum longus and soleus muscles in ex vivo contraction assays. (S)-β-Aminoisobutyric acid hydrochloride specifically protects osteocytes from oxidative stress-induced cell death .
    (S)-β-Aminoisobutyric acid hydrochloride
  • HY-113380R
    (S)-β-Aminoisobutyric acid (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    (S)-β-Aminoisobutyric acid (Standard) is the analytical standard of (S)-β-Aminoisobutyric acid. This product is intended for research and analytical applications. (S)-β-Aminoisobutyric acid is a non-protein amino acid originating from the catabolism of thymine and valine.
    (S)-β-Aminoisobutyric acid (Standard)
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-P11243
    EphA4 agonist compound 23

    		Ephrin Receptor Neurological Disease
    EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
    EphA4 agonist compound 23
  • HY-P10876
    mcK6A1

    		Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: